BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23085102)

  • 21. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
    Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
    J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
    Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
    Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
    Flavell DJ; Cooper S; Morland B; Flavell SU
    Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
    Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
    Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
    Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
    Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
    Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.
    Neiveyans M; Melhem R; Arnoult C; Bourquard T; Jarlier M; Busson M; Laroche A; Cerutti M; Pugnière M; Ternant D; Gaborit N; Chardès T; Poupon A; Gouilleux-Gruart V; Pèlegrin A; Poul MA
    MAbs; 2019 Apr; 11(3):593-605. PubMed ID: 30604643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.
    Qing Y; Shuo W; Zhihua W; Huifen Z; Ping L; Lijiang L; Xiaorong Z; Liming C; Daiwen X; Yu H; Wei X; Min F; Zuohua F; Guanxin S
    Cancer Immunol Immunother; 2006 Sep; 55(9):1111-21. PubMed ID: 16341531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
    Shimosaki S; Nakahata S; Ichikawa T; Kitanaka A; Kameda T; Hidaka T; Kubuki Y; Kurosawa G; Zhang L; Sudo Y; Shimoda K; Morishita K
    Biochem Biophys Res Commun; 2017 Mar; 485(1):144-151. PubMed ID: 28189691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells.
    Daniels TR; Neacato II; Rodríguez JA; Pandha HS; Morgan R; Penichet ML
    Leukemia; 2010 Sep; 24(9):1555-65. PubMed ID: 20574452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent.
    Holmes SE; Bachran C; Fuchs H; Weng A; Melzig MF; Flavell SU; Flavell DJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):42-55. PubMed ID: 25347443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity.
    Ippoliti R; Lendaro E; D'Agostino I; Fiani ML; Guidarini D; Vestri S; Benedetti PA; Brunori M
    FASEB J; 1995 Sep; 9(12):1220-5. PubMed ID: 7672515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel EpCAM-targeting monoclonal antibody 3-17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines.
    Lund K; Bostad M; Skarpen E; Braunagel M; Kiprijanov S; Krauss S; Duncan A; Høgset A; Selbo PK
    MAbs; 2014; 6(4):1038-50. PubMed ID: 24525727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.